Last Updated: 3 November 2026
Generic oral semaglutide in India is becoming an important development in the pharmaceutical industry. On 31 October 2026, Sun Pharmaceutical Industries reportedly received CDSCO approval for its generic oral semaglutide tablets in 3 mg, 7 mg and 14 mg strengths for the treatment of type 2 diabetes mellitus. This development could influence competition in India’s growing GLP-1 drug market.
According to an October 31, 2026 report by ET Pharma, the proposed once-daily oral formulation covers three strengths: 3 mg, 7 mg and 14 mg. The reported approval is for the treatment of type 2 diabetes mellitus.
However, the development has an important legal dimension. Novo Nordisk and Sun Pharma are involved in patent-related proceedings concerning oral semaglutide, and the Delhi High Court has issued directions relating to the proposed product’s commercial manufacture and launch.
This development is important not only for diabetes treatment but also for India’s generic pharmaceutical industry, oral peptide drug delivery technology, intellectual property rights and pharmaceutical regulatory affairs.
In this article, we examine the Sun Pharma semaglutide tablet approval, its scientific background, formulation technology, patent dispute and the possible implications for India’s pharmaceutical industry.
Generic Oral Semaglutide in India: Latest Approval Details
| Particular | Reported details |
|---|---|
| Company | Sun Pharmaceutical Industries |
| Drug | Semaglutide |
| Dosage form | Oral tablet |
| Strengths | 3 mg, 7 mg and 14 mg |
| Administration | Once daily |
| Reported indication | Type 2 diabetes mellitus |
| Regulatory authority | CDSCO, India |
| Manufacturing location | Kamrup, Assam |
| Regulatory development | Reported on 31 October 2026 |
| Legal proceedings | Delhi High Court |
| Next listed court date | 4 November 2026 |
The details above are based on the ET Pharma report and publicly available court orders. Regulatory approval should not automatically be interpreted as confirmation that the product is commercially available.
1. What Is the Latest News About Sun Pharma’s Generic Semaglutide Tablets?
On 31 October 2026, ET Pharma reported that Sun Pharmaceutical Industries had received CDSCO approval to manufacture and market its generic oral semaglutide formulation in India.
The reported formulation has three strengths:
- Semaglutide 3 mg
- Semaglutide 7 mg
- Semaglutide 14 mg
The tablets are intended for once-daily administration and have been reported for the treatment of type 2 diabetes.
According to the report, the formulation is of recombinant DNA (r-DNA) origin and is planned to be manufactured at Sun Pharma’s facility in Kamrup, Assam. The report also identifies a Chinese supplier as the source of the active pharmaceutical ingredient.
This development is significant because semaglutide is a peptide-based drug and developing an effective oral formulation requires specialised formulation technology.
Why is this approval important?
Unlike conventional small-molecule medicines, peptide drugs generally face considerable challenges when administered orally. They may undergo degradation in the gastrointestinal tract and have limited absorption through biological membranes.
Developing oral semaglutide therefore represents an important pharmaceutical formulation challenge.
Source: ET Pharma – Sun Pharma Wins CDSCO Nod for Semaglutide Pill
2. What Is Semaglutide?
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the management of type 2 diabetes and, in appropriately approved formulations and indications, obesity.
It is a modified peptide analogue of human GLP-1, a naturally occurring incretin hormone involved in glucose regulation and appetite control.
Semaglutide acts on GLP-1 receptors and produces several pharmacological effects.
Mechanism of Action of Semaglutide
The main pharmacological actions include:
- Increased insulin secretion: Semaglutide enhances insulin secretion in response to elevated blood glucose levels.
- Reduced glucagon secretion: It reduces inappropriate glucagon secretion, helping regulate blood glucose.
- Delayed gastric emptying: It slows gastric emptying, influencing the rate at which nutrients enter the small intestine.
- Appetite regulation: It acts on pathways involved in appetite and caloric intake, which can contribute to weight reduction.
Mechanism of Action Flowchart
GLP-1 receptor activation
↓
Glucose-dependent increase in insulin secretion
↓
Reduction in glucagon secretion
↓
Improved blood glucose regulation
In parallel:
GLP-1 receptor activation
↓
Reduced appetite and food intake
↓
Delayed gastric emptying
↓
Potential reduction in body weight
Semaglutide should not be described as simply an appetite suppressant. Its therapeutic effects involve multiple metabolic and physiological pathways.
3. Why Is Oral Semaglutide a Major Pharmaceutical Formulation Achievement?
Most peptide-based medicines are administered through injections because peptides generally have poor oral bioavailability.
There are several reasons for this:
A. Enzymatic degradation
Peptides can be degraded by digestive enzymes before reaching systemic circulation.
B. Poor membrane permeability
Their molecular size and physicochemical properties make it difficult to cross gastrointestinal epithelial membranes.
C. Low oral bioavailability
Only a small fraction of an orally administered peptide dose may reach systemic circulation.
Semaglutide presents these formulation challenges despite being developed in an oral dosage form.
Role of SNAC in Oral Semaglutide Formulation
An important formulation component associated with the established oral semaglutide reference product Rybelsus is salcaprozate sodium, commonly known as SNAC.
SNAC is an absorption enhancer.
Its role is to facilitate the absorption of semaglutide through the gastric mucosa.
The technology helps overcome some of the physiological barriers associated with oral peptide delivery.
The important point is that oral semaglutide formulation is not equivalent to simply converting an injectable formulation into a tablet.
It requires appropriate formulation design, absorption enhancement, stability considerations and bioavailability evaluation.
Scientific reference: NCBI – Oral and Injectable Pharmacological Agents for Type 2 Diabetes
4. Oral Semaglutide vs Injectable Semaglutide
Semaglutide is available in different pharmaceutical dosage forms depending on the specific product, approved indication and regulatory jurisdiction.
| Feature | Oral semaglutide | Injectable semaglutide |
|---|---|---|
| Dosage form | Tablet | Injection |
| Route | Oral | Subcutaneous |
| Administration | Usually once daily for established oral products | Usually once weekly for established injectable products |
| Absorption | Gastrointestinal absorption | Absorption from subcutaneous tissue |
| Formulation challenge | Peptide stability and oral absorption | Sterility, stability and injection delivery |
| Patient administration | Swallowed tablet | Injection device or syringe |
The oral and injectable dosage forms are not directly interchangeable on a milligram-to-milligram basis.
Their approved indications, strengths, dosing schedules and administration instructions can also differ.
Therefore, the approval of an oral formulation should not automatically be interpreted as approval for every indication associated with injectable semaglutide.
5. Semaglutide Patent Dispute in India: What Is Happening Between Sun Pharma and Novo Nordisk?
The legal background is one of the most important aspects of the current development.
Semaglutide-related intellectual property issues in India involve more than one patent and different aspects of pharmaceutical formulation technology.
The expiry of a patent relating to the active drug molecule does not automatically mean that every formulation-related patent has expired.
Understanding the Oral Semaglutide Patent Issue
The oral formulation of semaglutide has been associated with patent claims involving the use of semaglutide in combination with SNAC.
Novo Nordisk has pursued legal proceedings against several Indian pharmaceutical companies in relation to oral semaglutide formulations.
The Sun Pharma case is particularly important because the Delhi High Court has addressed questions concerning the composition of the proposed formulation and the amount or proportion of SNAC.
Delhi High Court Order: 11 August 2026
In its order dated 11 August 2026 in the matter involving Novo Nordisk and Sun Pharma, the Delhi High Court noted ambiguity regarding whether the proposed formulation contained SNAC and, if present, whether its proportion fell within the scope of Novo Nordisk’s patent claims.
The court directed that once a manufacturing licence was granted, Sun Pharma would need to approach the court for prior approval before taking steps towards commercial manufacturing or launching the product.
This direction is particularly important when distinguishing regulatory approval from permission to commercially launch a product.
Delhi High Court Order: 2 September 2026
In a subsequent order dated 2 September 2026, Sun Pharma sought permission to manufacture and market its proposed semaglutide formulation on specified parameters.
The company indicated that its proposed SNAC proportion would be outside the proportion or range claimed in Novo Nordisk’s patented formulation.
The court directed Sun Pharma to provide samples of the proposed 3 mg, 7 mg and 14 mg tablets to Novo Nordisk for examination.
The matter was listed for 4 November 2026.
What Is the Current Legal Position?
As of 3 November 2026:
- ET Pharma has reported CDSCO approval for Sun Pharma’s oral semaglutide product.
- Patent-related proceedings between Novo Nordisk and Sun Pharma are ongoing.
- The Delhi High Court had directed the company to seek prior approval before commercial manufacturing or launch.
- Samples of the proposed formulation were directed to be supplied.
- The next listed court date is 4 November 2026.
Therefore, regulatory approval and commercial launch status should be treated as separate issues.
The latest court position should be checked again after the 4 November hearing.
Court references:
6. Has Generic Oral Semaglutide Already Launched in India?
Yes. It is important to understand that Sun Pharma is not the first Indian pharmaceutical company to launch generic oral semaglutide.
Torrent Pharmaceuticals announced the launch of oral and injectable semaglutide formulations in India on 21 March 2026 under the brand names Sembolic and Semalix.
The launch was announced following developments in semaglutide patent litigation.
This distinction matters because the generic semaglutide market in India was already developing before the latest Sun Pharma approval.
The entry of additional pharmaceutical companies could further increase competition in the GLP-1 segment.
Source: Torrent Pharmaceuticals – Official Media Release, 21 March 2026
7. What Could Sun Pharma’s Approval Mean for the Indian Pharmaceutical Industry?
The development could have several implications for the Indian pharmaceutical sector.
A. Increased Competition in the GLP-1 Drug Market
More pharmaceutical companies entering the semaglutide segment could increase competition.
Companies may compete through manufacturing capabilities, formulation development, pricing, product quality and distribution networks.
B. Growth of Peptide-Based Drug Manufacturing
Peptide therapeutics require specialised manufacturing and quality control processes.
The growth of semaglutide products may encourage further investment in peptide synthesis, biotechnology-based production, analytical testing and advanced formulation research.
C. Opportunities in Oral Drug Delivery Research
Oral peptide delivery remains an important area of pharmaceutical research.
Researchers are exploring different approaches to improve:
- Peptide stability.
- Gastrointestinal absorption.
- Bioavailability.
- Permeation enhancement.
- Formulation performance.
These developments create opportunities for pharmaceutical scientists working in Pharmaceutics, Novel Drug Delivery Systems and Pharmaceutical Technology.
D. Greater Importance of Intellectual Property Rights
The current dispute also demonstrates that pharmaceutical product development involves more than obtaining regulatory approval.
Companies must consider:
- Patent claims.
- Formulation composition.
- Freedom-to-operate assessments.
- Manufacturing permissions.
- Regulatory compliance.
- Commercial launch restrictions.
For students and professionals interested in these subjects, understanding patent and regulatory requirements is becoming increasingly important.
You can also explore our detailed guide on Regulatory Affairs Careers in India to understand how regulatory professionals work in the pharmaceutical industry.
8. Safety and Important Pharmaceutical Considerations
Semaglutide is a prescription medicine and should not be used without appropriate medical supervision.
Common adverse reactions reported with established oral semaglutide products include:
- Nausea.
- Vomiting.
- Diarrhoea.
- Abdominal pain.
- Decreased appetite.
- Constipation.
Important safety considerations can also include pancreatitis, gallbladder-related complications, dehydration and other product-specific warnings.
The actual warnings, contraindications and administration instructions must always be checked against the approved prescribing information for the individual product.
It is also important to distinguish the indications of different semaglutide products.
The reported Sun Pharma approval discussed in this article concerns type 2 diabetes. Readers should not assume that this automatically permits the product to be used for obesity treatment.
Patients should never start, stop or change a semaglutide dose without consulting a qualified healthcare professional.
Reference: FDA – Rybelsus Prescribing Information
9. Frequently Asked Questions About Generic Semaglutide in India
Q1. Has Sun Pharma received CDSCO approval for generic semaglutide tablets?
According to an ET Pharma report published on 31 October 2026, Sun Pharma has received regulatory approval to manufacture and market its generic oral semaglutide tablets in India.
Q2. What are the strengths of Sun Pharma’s generic oral semaglutide tablets?
The reported strengths are 3 mg, 7 mg and 14 mg.
These strengths should not be interpreted as instructions for self-medication. The approved prescribing information determines the appropriate dosing schedule.
Q3. What is the approved indication of Sun Pharma’s oral semaglutide formulation?
The reported approval covers treatment of type 2 diabetes mellitus.
The approval should not automatically be interpreted as approval for obesity treatment.
Q4. Is Sun Pharma’s generic semaglutide tablet available in the Indian market?
The regulatory approval has been reported, but commercial launch and current market availability should be independently confirmed.
The company is also involved in ongoing patent-related proceedings before the Delhi High Court. The matter was listed for 4 November 2026.
Q5. What is SNAC in oral semaglutide tablets?
SNAC stands for salcaprozate sodium. It is an absorption enhancer used in the established oral semaglutide reference formulation Rybelsus to facilitate gastrointestinal absorption.
The exact excipient composition of Sun Pharma’s proposed formulation should not be assumed from the composition of another product.
Q6. What is the difference between oral and injectable semaglutide?
Oral semaglutide is administered as a tablet, while injectable semaglutide is administered subcutaneously.
They have different absorption characteristics, formulation requirements and product-specific dosing instructions.
Q7. Is semaglutide a GLP-1 receptor agonist?
Yes. Semaglutide activates GLP-1 receptors and helps regulate blood glucose through glucose-dependent effects on insulin and glucagon secretion. It also influences appetite and gastric emptying.
Q8. Why is oral semaglutide difficult to formulate?
Semaglutide is a peptide molecule that can face enzymatic degradation and poor gastrointestinal absorption. Formulation technologies and absorption enhancers are therefore important for developing effective oral semaglutide tablets.
Q9. Which Indian company first launched generic oral semaglutide?
Torrent Pharmaceuticals announced the launch of its oral and injectable semaglutide products under the brands Sembolic and Semalix on 21 March 2026.
Q10. What is the significance of the Sun Pharma–Novo Nordisk patent dispute?
The dispute highlights the importance of formulation-related patent claims, SNAC composition, intellectual property rights and the legal requirements associated with commercialising generic oral semaglutide products.
10. Conclusion
The generic oral semaglutide in India development represents an important milestone for pharmaceutical formulation research, regulatory affairs and competition in the Indian diabetes treatment market.
Sun Pharma’s reported CDSCO approval for generic oral semaglutide tablets represents an important development in India’s pharmaceutical industry.
The availability of additional generic products could increase competition in the GLP-1 drug segment and create opportunities in peptide-based drug manufacturing, formulation technology and pharmaceutical research.
However, the ongoing patent dispute between Novo Nordisk and Sun Pharma demonstrates that pharmaceutical innovation is not limited to drug development and regulatory approval.
Intellectual property rights, formulation design, manufacturing permissions and commercial launch requirements are equally important.
The next important development is the Delhi High Court proceeding listed for 4 November 2026, which may provide further clarity regarding the commercialisation of Sun Pharma’s proposed oral semaglutide product.
For pharmacy students and pharmaceutical professionals, this development is an excellent example of how Pharmaceutics, Pharmacology, Biotechnology, Regulatory Affairs and Pharmaceutical Patent Law intersect in the development of a modern medicine.
References and Further Reading
- ET Pharma – Sun Pharma Wins CDSCO Nod for Semaglutide Pill (31 October 2026)
- Delhi High Court – Novo Nordisk vs Sun Pharma (11 August 2026)
- Delhi High Court – Novo Nordisk vs Sun Pharma (2 September 2026)
- Torrent Pharmaceuticals – Semaglutide Launch Press Release (21 March 2026)
- NCBI Bookshelf – Oral and Injectable Pharmacological Agents for Type 2 Diabetes
- FDA – Rybelsus Prescribing Information
Disclaimer: This article is intended for pharmaceutical education and industry information. It does not replace medical advice, professional prescribing information or official regulatory notifications. Regulatory and commercial status may change as further decisions are announced.